Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-08 6:24 pm Purchase | 2023-12-31 | 13G | RayzeBio, Inc. Common Stock RYZB | Versant Venture Capital VII L.P. | 4,565,015 7.600% | 4,565,015 (New Position) | Filing History |
| 2023-03-10 4:13 pm Sale | 2023-03-01 | 13D | Chinook Therapeutics, Inc. KDNY | Versant Venture Capital VII L.P. | 2,105,107 3.200% | -240,000 (-10.23%) | Filing History |
| 2022-12-28 4:07 pm Sale | 2022-12-22 | 13D | Chinook Therapeutics, Inc. KDNY | Versant Venture Capital VII L.P. | 2,345,107 3.700% | -567,963 (-19.50%) | Filing History |
| 2022-08-22 4:15 pm Unchanged | 2022-08-12 | 13D | Chinook Therapeutics, Inc. KDNY | Versant Venture Capital VII L.P. | 2,913,070 4.600% | 0 (Unchanged) | Filing History |
| 2022-04-13 4:43 pm Sale | 2022-04-04 | 13D | Chinook Therapeutics, Inc. KDNY | Versant Venture Capital VII L.P. | 2,913,070 5.300% | -709,953 (-19.60%) | Filing History |
| 2022-01-13 4:30 pm Sale | 2022-01-03 | 13D | Chinook Therapeutics, Inc. KDNY | Versant Venture Capital VII L.P. | 3,623,023 6.700% | -600,000 (-14.21%) | Filing History |
| 2021-09-07 5:13 pm Sale | 2021-08-27 | 13D | Chinook Therapeutics, Inc. KDNY | Versant Venture Capital VII L.P. | 4,223,023 9.400% | -510,000 (-10.78%) | Filing History |